Skip to main content

Table 1

From: Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine

  N BL HIV-RNA BL CD4 W24 CD4
Group A: RAL+MVC+ETR 15 4.2(3.9–5.1) 276(90–528) 552(398–718)
Group B: RAL + MVC or ETR + PI sparing OBT** 17 4.0(3.9–4.7) 197(94–295) 378(330–447)
Group C: RAL + MVC or ETR +PI/r* based OBT** 20 4.7(3.8–5.3) 160(63–198) 306(239–361)
Group D: RAL + PI/r* based OBT** 16 4.2(3.6–4.9) 240(121–329) 349(276–504)
  1. *in 33/36 darunavir/r **OBT = optimized background therapy.